Compile Data Set for Download or QSAR
Report error Found 23 Enz. Inhib. hit(s) with all data for entry = 11942
TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663069(2-((2S)-4-(8-fluoro-2- ((S)-1-methylpyrrolidin- 2-...)
Affinity DataIC50: 0.490nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663067(2-((2S)-4-(8-fluoro-2- ((2R,7aS)-2- fluorotetrahyd...)
Affinity DataIC50: 0.590nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663064(US20240109893, Example 854)
Affinity DataIC50: 0.590nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663068(2-((2S)-1-acryloyl-4- (8-fluoro-2-((S)-1- methylpy...)
Affinity DataIC50: 0.710nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663066(2-((2S)-1-acryloyl-4-(8- fluoro-2-((2R,7aS)-2- flu...)
Affinity DataIC50: 0.710nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663065(2-((2S)-1-acryloyl-4- (8-fluoro-2-((S)-1- methylpy...)
Affinity DataIC50: 0.790nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663072(2-((S)-4-(7-(8- chloronaphthalen-1- yl)-8-fluoro- ...)
Affinity DataIC50: 0.890nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663073(2-((S)-4-(7-(8- chloronaphthalen-1- yl)-8-fluoro- ...)
Affinity DataIC50: 0.930nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663070(2-((2S)-4-(8-fluoro-2- ((2R,7aS)-2- fluorotetrahyd...)
Affinity DataIC50: 1.02nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663071(2-((2S)-1-acryloyl-4- (2-((S)-1- methylpyrrolidin-...)
Affinity DataIC50: 1.29nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663061(2-((S)-1-acryloyl-4-(6-fluoro-7-(8-chloro-7- fluor...)
Affinity DataIC50: 1.32nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663056(US20240109893, Example 73 | US20240109893, Example...)
Affinity DataIC50: 1.34nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663060(2-((S)-1-acryloyl-4-(6-fluoro-7-(8-chloronaphthale...)
Affinity DataIC50: 1.44nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663055(2-((S)-1-acryloyl-4-(8-fluoro-7-(4-fluoro-5,6,7,8-...)
Affinity DataIC50: 1.65nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663062(2-((S)-1-acryloyl-4-(6-chloro-7-(8-chloronaphthale...)
Affinity DataIC50: 2.23nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663059(2-((S)-1-acryloyl-4-(7-(8-chloronaphthalen-1-yl)-8...)
Affinity DataIC50: 2.40nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663063(US20240109893, Example 840)
Affinity DataIC50: 4.52nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663054(2-fluoro-1-((1R,5R)-6-(8-fluoro-2-(((S)-1- methylp...)
Affinity DataIC50: 8nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663056(US20240109893, Example 73 | US20240109893, Example...)
Affinity DataIC50: 8.90nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663058(2-((S)-1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-...)
Affinity DataIC50: 9.91nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663052(US20240109893, Example 2)
Affinity DataIC50: 10.6nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663053(US20240109893, Example 3)
Affinity DataIC50: 13.8nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent

TargetGTPase KRas [G12C](Human)
Shanghai Kechow Pharma

US Patent
LigandPNGBDBM663051(US20240109893, Example 1)
Affinity DataIC50: 20.3nMAssay Description:1. Serially 4×-diluted compounds (10 concentration points in total) were separately premixed with KRAS G12C-GDP (ICE, Kras 20191018) in a reaction bu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2024
Entry Details
Go to US Patent